Warrendale, PA – According to filings with the U.S. Securities and Exchange Commission, ECM Therapeutics is raising $10,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, Paul Fagan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ECM Therapeutics

ECM Therapeutics, Inc. is Advancing regenerative medicine through the development of a natural biomaterial that restores mother nature’s template to treat disease and injury. ECM Therapeutics’ patented ECM hydrogel technology allows for expanded, less invasive applications in multiple disease areas. The first clinical product, EsophaGel, treats Barrett’s esophagus, a precancerous condition that currently has no effective therapy.

To learn more about ECM Therapeutics, visit http://ecmtherapeutics.com/

Contact:
Paul Fagan, Chief Executive Officer
412-287-3767
pfagan@ecmtherapeutics.com
https://www.linkedin.com/in/paul-fagan-80b072168/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved